• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌转录组谱分析揭示 TGF-β 通路的表观遗传抑制。

Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

Genome Res. 2011 Jan;21(1):74-82. doi: 10.1101/gr.108803.110. Epub 2010 Dec 14.

DOI:10.1101/gr.108803.110
PMID:21156726
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3012928/
Abstract

Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies. Diagnosis usually occurs after metastatic spread, largely reflecting vague symptoms of early disease combined with lack of an effective screening strategy. Epigenetic mechanisms of gene regulation, including DNA methylation, are fundamental to normal cellular function and also play a major role in carcinogenesis. To elucidate the biological and clinical relevance of DNA methylation in ovarian cancer, we conducted expression microarray analysis of 39 cell lines and 17 primary culture specimens grown in the presence or absence of DNA methyltransferase (DNMT) inhibitors. Two parameters, induction of expression and standard deviation among untreated samples, identified 378 candidate methylated genes, many relevant to TGF-beta signaling. We analyzed 43 of these genes and they all exhibited methylation. Treatment with DNMT inhibitors increased TGF-beta pathway activity. Hierarchical clustering of ovarian cancers using the 378 genes reproducibly generated a distinct gene cluster strongly correlated with TGF-beta pathway activity that discriminates patients based on age. These data suggest that accumulation of age-related epigenetic modifications leads to suppression of TGF-beta signaling and contributes to ovarian carcinogenesis.

摘要

上皮性卵巢癌是妇科恶性肿瘤死亡的主要原因。诊断通常发生在转移扩散后,这主要反映了早期疾病的模糊症状,加上缺乏有效的筛查策略。基因调控的表观遗传机制,包括 DNA 甲基化,是正常细胞功能的基础,在肿瘤发生中也起着重要作用。为了阐明 DNA 甲基化在卵巢癌中的生物学和临床相关性,我们对 39 种细胞系和 17 种原代培养标本进行了表达微阵列分析,这些标本在存在或不存在 DNA 甲基转移酶 (DNMT) 抑制剂的情况下生长。两个参数,诱导表达和未处理样品的标准差,确定了 378 个候选甲基化基因,其中许多与 TGF-β 信号通路相关。我们分析了其中的 43 个基因,它们都显示出甲基化。DNMT 抑制剂的处理增加了 TGF-β 通路的活性。使用这 378 个基因对卵巢癌进行层次聚类,可重现性地产生一个与 TGF-β 通路活性密切相关的独特基因簇,该基因簇可根据年龄区分患者。这些数据表明,与年龄相关的表观遗传修饰的积累导致 TGF-β 信号通路的抑制,并促进卵巢癌的发生。

相似文献

1
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.卵巢癌转录组谱分析揭示 TGF-β 通路的表观遗传抑制。
Genome Res. 2011 Jan;21(1):74-82. doi: 10.1101/gr.108803.110. Epub 2010 Dec 14.
2
TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.转化生长因子-β在卵巢癌细胞上皮-间质转化过程中诱导DNA甲基化的整体变化。
Epigenetics. 2014 Nov;9(11):1461-72. doi: 10.4161/15592294.2014.971608.
3
Cytidine monophosphate kinase is inhibited by the TGF-β signalling pathway through the upregulation of miR-130b-3p in human epithelial ovarian cancer.在人上皮性卵巢癌中,胞苷单磷酸激酶通过miR-130b-3p的上调被转化生长因子-β信号通路抑制。
Cell Signal. 2017 Jul;35:197-207. doi: 10.1016/j.cellsig.2017.04.009. Epub 2017 Apr 14.
4
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.POSTN/TGFBI 相关的基质特征可预测浆液性上皮性卵巢癌的不良预后。
Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.
5
DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.DNA低甲基化介导的癌症/睾丸抗原45(CT45)基因激活与上皮性卵巢癌的疾病进展和生存期缩短相关。
Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.
6
Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.全面的卵巢肿瘤甲基化组分析揭示了 hedgehog 信号通路调节剂作为预后 DNA 甲基化生物标志物。
Epigenetics. 2013 Jun;8(6):624-34. doi: 10.4161/epi.24816. Epub 2013 May 10.
7
Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway.人类上皮型卵巢肿瘤标志物β2微球蛋白受转化生长因子-β信号通路调控。
J Transl Med. 2016 Mar 16;14:75. doi: 10.1186/s12967-016-0832-x.
8
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.异常的 TGFβ/SMAD4 信号通路导致卵巢癌中假定的肿瘤抑制因子 RunX1T1 的表观遗传沉默。
Epigenetics. 2011 Jun;6(6):727-39. doi: 10.4161/epi.6.6.15856. Epub 2011 Jun 1.
9
Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.血管生成相关因子在卵巢癌休眠和复发性生长过程中的表达及其表观遗传调控。
Epigenetics. 2013 Dec;8(12):1330-46. doi: 10.4161/epi.26675. Epub 2013 Oct 17.
10
Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.Crk样衔接蛋白是上皮性卵巢癌中转化生长因子-β诱导的AKT和ERK信号通路所必需的。
Tumour Biol. 2015 Feb;36(2):915-9. doi: 10.1007/s13277-014-2724-0. Epub 2014 Oct 12.

引用本文的文献

1
MYO1F in neutrophils is required for the response to immune checkpoint blockade therapy.中性粒细胞中的MYO1F是免疫检查点阻断疗法应答所必需的。
J Exp Med. 2025 Jun 2;222(6). doi: 10.1084/jem.20241957. Epub 2025 Apr 9.
2
Genomic analyses of intricate interaction of TE-lncRNA overlapping genes with miRNAs in human diseases.人类疾病中 TE-lncRNA 重叠基因与 miRNAs 复杂相互作用的基因组分析。
Genes Genomics. 2024 Nov;46(11):1313-1325. doi: 10.1007/s13258-024-01547-1. Epub 2024 Aug 31.
3
Association analysis of FXYD5 with prognosis and immunological characteristics across pan-cancer.FXYD5在泛癌中的预后及免疫特征的关联分析
Heliyon. 2024 May 9;10(9):e30727. doi: 10.1016/j.heliyon.2024.e30727. eCollection 2024 May 15.
4
Current data and future perspectives on DNA methylation in ovarian cancer (Review).当前关于卵巢癌中 DNA 甲基化的研究数据和未来展望(综述)。
Int J Oncol. 2024 Jun;64(6). doi: 10.3892/ijo.2024.5650. Epub 2024 May 17.
5
Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.联合抑制 WEE1 和 ATR 治疗卵巢透明细胞癌。
J Ovarian Res. 2023 Apr 22;16(1):80. doi: 10.1186/s13048-023-01160-y.
6
Epigenetic Regulation of Claudin-1 in the Development of Ovarian Cancer Recurrence and Drug Resistance.紧密连接蛋白-1在卵巢癌复发和耐药发生发展中的表观遗传调控
Front Oncol. 2021 Mar 22;11:620873. doi: 10.3389/fonc.2021.620873. eCollection 2021.
7
Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.同时抑制赖氨酸特异性去甲基化酶1(LSD1)和转化生长因子β(TGFβ)可通过抗程序性死亡蛋白1(PD-1)治疗根除低免疫原性肿瘤。
Cancer Discov. 2021 Aug;11(8):1970-1981. doi: 10.1158/2159-8290.CD-20-0017. Epub 2021 Mar 9.
8
TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.TIMP-2 调节卵巢癌细胞的增殖、侵袭和 STAT3 介导的肿瘤干细胞依赖性化疗耐药性。
BMC Cancer. 2020 Oct 6;20(1):960. doi: 10.1186/s12885-020-07274-6.
9
MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread.miRNA-200 家族调控卵巢包涵囊肿形成和卵巢癌转移方式。
Oncogene. 2020 May;39(20):4045-4060. doi: 10.1038/s41388-020-1264-x. Epub 2020 Mar 25.
10
Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.分析基因表达特征可识别预后和功能不同的卵巢透明细胞癌亚型。
EBioMedicine. 2019 Dec;50:203-210. doi: 10.1016/j.ebiom.2019.11.017. Epub 2019 Nov 21.

本文引用的文献

1
Targeting slow-proliferating ovarian cancer cells.靶向生长缓慢的卵巢癌细胞。
Int J Cancer. 2010 May 15;126(10):2448-56. doi: 10.1002/ijc.24919.
2
5'-azacytidine expression arrays.5'-氮杂胞苷表达阵列。
Methods Mol Biol. 2009;507:165-74. doi: 10.1007/978-1-59745-522-0_13.
3
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.CD133的表观遗传调控与CD133+卵巢癌细胞的致瘤性
Oncogene. 2009 Jan 15;28(2):209-18. doi: 10.1038/onc.2008.374. Epub 2008 Oct 6.
4
Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3.蜗牛蛋白和蛞蝓蛋白通过β-连环蛋白-T细胞因子4依赖的转化生长因子-β3表达促进上皮-间质转化。
Mol Biol Cell. 2008 Nov;19(11):4875-87. doi: 10.1091/mbc.e08-05-0506. Epub 2008 Sep 17.
5
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.浆液性和子宫内膜样卵巢癌的新型分子亚型与临床结局相关。
Clin Cancer Res. 2008 Aug 15;14(16):5198-208. doi: 10.1158/1078-0432.CCR-08-0196.
6
TGFbeta in Cancer.癌症中的转化生长因子β
Cell. 2008 Jul 25;134(2):215-30. doi: 10.1016/j.cell.2008.07.001.
7
Patterns of cell signaling pathway activation that characterize mammary development.表征乳腺发育的细胞信号通路激活模式。
Development. 2008 Aug;135(14):2403-13. doi: 10.1242/dev.019018. Epub 2008 Jun 11.
8
Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.转化生长因子-β1、转化生长因子-β2和转化生长因子-β3通过诱导Smad3依赖的上皮-间质转化增强卵巢癌转移潜能。
Mol Cancer Res. 2008 May;6(5):695-705. doi: 10.1158/1541-7786.MCR-07-0294.
9
DNA methylation landscapes: provocative insights from epigenomics.DNA甲基化图谱:表观基因组学的前沿见解
Nat Rev Genet. 2008 Jun;9(6):465-76. doi: 10.1038/nrg2341.
10
Genome-wide promoter analysis uncovers portions of the cancer methylome.全基因组启动子分析揭示了癌症甲基化组的部分情况。
Cancer Res. 2008 Apr 15;68(8):2661-70. doi: 10.1158/0008-5472.CAN-07-5913.